Literature DB >> 15718552

Selective serotonin reuptake inhibitors: THREAD trial may show way forward.

Robert Peveler, Tony Kendrick.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 15718552      PMCID： PMC549151          DOI： 10.1136/bmj.330.7488.420-b

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years.

Authors:  J E Barrett; J W Williams; T E Oxman; E Frank; W Katon; M Sullivan; M T Hegel; J E Cornell; A S Sengupta
Journal:  J Fam Pract       Date:  2001-05       Impact factor: 0.493

2.  Selective serotonin reuptake inhibitors.

Authors:  John R Geddes; Andrea Cipriani
Journal:  BMJ       Date:  2004-10-09

3.  Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial.

Authors:  E S Paykel; J A Hollyman; P Freeling; P Sedgwick
Journal:  J Affect Disord       Date:  1988 Jan-Feb       Impact factor: 4.839

4.  Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder.

Authors:  Lewis L Judd; Mark Hyman Rapaport; Kimberly A Yonkers; A John Rush; Ellen Frank; Michael E Thase; David J Kupfer; John M Plewes; Pamela J Schettler; Gary Tollefson
Journal:  Am J Psychiatry       Date:  2004-10       Impact factor: 18.112
  4 in total
  4 in total

1.  HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort.

Authors:  Taro Kishi; Reiji Yoshimura; Tsuyoshi Kitajima; Tomo Okochi; Takenori Okumura; Tomoko Tsunoka; Yoshio Yamanouchi; Yoko Kinoshita; Kunihiro Kawashima; Hiroshi Naitoh; Jun Nakamura; Norio Ozaki; Nakao Iwata
Journal:  Neuromolecular Med       Date:  2009-11-24       Impact factor: 3.843

2.  Translin-associated factor X gene (TSNAX) may be associated with female major depressive disorder in the Japanese population.

Authors:  Akiko Okuda; Taro Kishi; Tomo Okochi; Masashi Ikeda; Tsuyoshi Kitajima; Tomoko Tsunoka; Takenori Okumukura; Yasuhisa Fukuo; Yoko Kinoshita; Kunihiro Kawashima; Yoshio Yamanouchi; Toshiya Inada; Norio Ozaki; Nakao Iwata
Journal:  Neuromolecular Med       Date:  2009-09-04       Impact factor: 3.843

3.  CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients.

Authors:  Taro Kishi; Tsuyoshi Kitajima; Masashi Ikeda; Yoshio Yamanouchi; Yoko Kinoshita; Kunihiro Kawashima; Tomo Okochi; Takenori Okumura; Tomoko Tsunoka; Norio Ozaki; Nakao Iwata
Journal:  Neuromolecular Med       Date:  2009-04-04       Impact factor: 3.843

4.  Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.

Authors:  D G S Perahia; D K Kajdasz; D J Walker; J Raskin; A Tylee
Journal:  Int J Clin Pract       Date:  2006-05       Impact factor: 2.503
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.